Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TACE Combined With Camrelizumab and Apatinib Versus TACE in Intermediate and Advanced Hepatocelluar Carcinoma: a Randomized, Open-label, Multi-center Clinical Trials

NCT04559607 is registered in ClinicalTrials.gov with Zhongda Hospital as lead sponsor.

NCT NCT04559607
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04559607 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TACE Combined With Camrelizumab and Apatinib Versus TACE in Intermediate and Advanced Hepatocelluar Carcinoma: a Randomized, Open-label, Multi-center Clinical Trials
Lead sponsor
Zhongda Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
September 11, 2020
Completion date
January 31, 2026
Enrollment
188 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma